吸入一氧化氮在极早产儿呼吸窘迫综合征中的应用
BACKGROUND: Inhaled nitric oxide (iNO) is increasingly prescribed to extremely premature neonates with respiratory distress syndrome (RDS). Most of this off-label use occurs during the first week of life.…
要点
- 在极早产儿RDS中,iNO超说明书使用与住院死亡率无显著降低相关。
- 研究样本中2.6%的极早产儿接受了iNO治疗,多发生在生后第一周。
核心结论
- 极早产儿RDS超说明书使用iNO与住院死亡率降低无关。
研究设计与样本
- 回顾性队列研究,数据来自Pediatrix医疗集团临床数据仓库,纳入2004至2014年胎龄22至29周单胎、因RDS需机械通气且无畸形的极早产儿。
- 采用序贯风险集方法,将生后7天内接受iNO的患者按倾向性评分与未接受iNO者1:1匹配,共993例接受iNO(2.6%),匹配队列各971例。
- 使用Cox比例风险回归模型,以年龄为时间尺度评估iNO与住院死亡率的关联。
临床怎么用
- 对于极早产儿RDS,不应期望通过超说明书使用iNO来降低住院死亡率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inhaled nitric oxide (iNO) is increasingly prescribed to extremely premature neonates with respiratory distress syndrome (RDS). Most of this off-label use occurs during the first week of life. We studied this practice, hypothesizing that it would not be associated with improved survival. METHODS: We queried the Pediatrix Medical Group Clinical Data Warehouse to identify all neonates born at 22 to 29 weeks' gestation from 2004 to 2014. In our study sample, we included singletons who required mechanical ventilation for treatment of RDS and excluded those with anomalies. The primary outcome was death before discharge. Through a sequential risk set approach, each patient who received iNO during the first 7 days of life ("case patient") was matched by using propensity scores to a patient who had not received iNO at a chronological age before the case patient's iNO initiation age (defined as the index age for the matched pair). The association between iNO status and in-hospital mortality was evaluated in a Cox proportional hazards regression model by using age as the time scale with patients entering the risk set at their respective index age. RESULTS: Among 37 909 neonates in our study sample, we identified 993 (2.6%) who received iNO. The 2 matched cohorts each contained 971 patients. We did not observe a significant association between iNO exposure and mortality (hazard ratio, 1.08; 95% confidence interval, 0.94-1.25; P = .29). CONCLUSIONS: Off-label prescription of iNO is not associated with reduced in-hospital mortality among extremely premature neonates with RDS.
引用
- Carey WA, Weaver AL, Mara KC, et al. Inhaled Nitric Oxide in Extremely Premature Neonates With Respiratory Distress Syndrome. Pediatrics. 2018. PMID: 29439205. doi:10.1542/peds.2017-3108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。